Palatin Technologies (PTN) vs Quantum Biopharma (QNTM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Quantum Biopharma (QNTM) has outperformed Palatin Technologies (PTN) over the past year, losing 77.6% versus a loss of 79.9%. Over five years, QNTM leads with a -98.5% price change compared with -99.3% for PTN. Quantum Biopharma is the larger company by market cap ($8.3 million vs $8.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PTN | QNTM |
|---|---|---|
| Share price | $4.58 | $1.29 |
| Market cap | $8.16M | $8.29M |
| 1-day change | -7.10% | -9.15% |
| YTD return | -70.22% | -82.33% |
| 1-year return | -79.93% | -77.60% |
| 5-year return | -99.35% | -98.51% |
| EPS (TTM) | $-2.96 | $-3.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $8.83M | — |
| Net income (latest FY) | $-8.38M | — |
| Operating margin | -98.17% | — |
| Net margin | -94.88% | — |
| 52-week high | $31.00 | $12.42 |
| 52-week low | $4.51 | $1.26 |
| Distance from 52-week high | -85.23% | -89.61% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1068.12% | +851.16% |
| Average volume | 71.93K | 148.83K |
| Shares outstanding | 1.78M | 6.43M |
| Employees | 25 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Palatin Technologies
PTN stock →Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
About Quantum Biopharma
QNTM stock →Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments.
Health Care · Biotechnology: Pharmaceutical Preparations
PTN vs QNTM FAQ
Which is bigger, Palatin Technologies or Quantum Biopharma?
Quantum Biopharma (QNTM) is larger, with a market capitalization of $8.29M compared with $8.16M for Palatin Technologies (PTN).
Which stock has performed better over the past year, PTN or QNTM?
QNTM returned -77.60% over the past 12 months, compared with -79.93% for PTN (price return, excluding dividends). Past performance does not predict future results.
Are Palatin Technologies and Quantum Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.